Tagged with S

Czech Republic Emmanuelle Boishardy joined GSK in France 20 years ago. In 2017, she embarked on her first assignment as General Manager – in the Czech affiliate. She recounts how she adapted to her new position in a foreign country and turned the affiliate around by overhauling compliance processes and successful launches…

Hungary József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D in their internationalization strategy, and the long-term vision of the company.   Healthcare elements are increasingly expensive, and the burden…

CEE With a footprint of over 20 years in the Czech Republic, Gedeon Richter’s affiliate here is a key pillar to the company’s success in the Central Eastern European region. Corina Croitoru, Managing Director for the Czech Republic and Slovakia, evaluates the challenges that come with bringing to market medicines on…

Hungary Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the country’s pharma and healthcare ecosystem. Furthermore, Szabó highlights the offering Szinapszis can deliver as a partner of choice to both…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Europe The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart.   The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player   Europe has a history as a world leader in medical innovation,…

China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…

Hungary After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions with the aim of bringing Hungary in line with other countries at the forefront of digital healthcare   The Road…

UAE As part of its endeavour to provide world-class healthcare, on December 10 2019, the Abu Dhabi Department of Health (DoH) announced a national program to use large-scale genomic data with the aim of allowing doctors working in the Emirate to provide more personalized and preventive treatment.   The Genome Program…

Hungary Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to offer her expert insights into key trends impacting the Hungarian healthcare ecosystem in areas such as in vitro fertilization, market…

Czech Republic Josef Kredba, country manager Czech Republic at G.L. Pharma, an Austrian pharmaceutical company, explains how the company has returned to growth in the challenging Czech generics market and shares his thoughts on market access and pricing conditions for both innovative and generic products.   On the one hand, authorities recognize…

Hungary Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in Hungary. Langen describes the importance of clinical evidence and product quality in the company’s portfolio and the advantages that Phytotec…